Roche Sales Decline on Currency Hit
By Helena Smolak
Roche first-quarter sales declined amid weak demand for Covid-19 products and currency headwinds but slightly beat analysts expectations.
The Swiss pharmaceutical giant said Wednesday that sales dropped to 14.39 billion Swiss francs ($15.79 billion) for the first quarter, from CHF15.32 billion in the same quarter a year prior. Analysts had estimated sales at CHF14.35 billion, according to a Visible Alpha compiled consensus.
Sales in the pharmaceutical and diagnostics divisions both fell 6% to CHF10.92 billion and CHF3.48 billion, respectively, the company said.
Sales related to Covid-19 tests dropped to CHF100 million in the first quarter, down from CHF300 million a year before, as booming demand for Covid-19 medicine Ronapreve and tests waned.
Roche said this quarter was the last to be hit by pandemic-related sales decline. Foreign-exchange rates also hurt sales, and Roche said its revenue growth on-year was 2%, when measured at constant currency.
Roche backed its full-year guidance and expects to further increase its dividend.
Write to Helena Smolak at helena.smolak@wsj.com
Corrections & Amplifications
This article was corrected at 0624 GMT to reflect sales at Roche's pharmaceutical and diagnostics divisions both fell 6%, to CHF10.92 billion and CHF3.48 billion, respectively. The original version incorrectly stated the figures as CHF75.8 billion and CHF24.2 billion, respectively.
(END) Dow Jones Newswires
April 24, 2024 01:49 ET (05:49 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Berkshire Hathaway Stock a Buy, a Sell, or Fairly Valued?
-
For Bond Investors, Delayed Rate Cuts Demand a Different Playbook
-
What’s Happening In the Markets This Week
-
How the Tokyo Stock Exchange Is Pushing for Better Shareholder Returns
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Where We See Opportunities After an Ugly Month for Stocks
-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
Berkshire Hathaway Earnings: Strong Insurance Results Continue to Lift Revenue and Profitability
-
10 Questions for Berkshire Hathaway’s 2024 Annual Meeting
-
After Earnings, Is Ford Stock a Buy, a Sell, or Fairly Valued?
-
3 Dividend Stocks for May 2024
-
Amgen Earnings: Obesity Drug Update Is Highly Encouraging
-
What’s Going on With Apple, Tesla, and Alphabet?
-
Apple Earnings: A Weak 2024, but Optimism for 2025
-
4 Utility Stocks to Play the AI Data Center Boom